Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Spotlight Article

Innovative Technologies for CAR-T Manufacturing: the Key to Commercialization

Latest Advances in CAR-T Cell Manufacture & Clinical Developments

Stanley Kowalski & Daniella Kranjac

Stanley Kowalski is Co-founder and CEO of FloDesign Sonics, Inc. In this role, he is responsible for the direction and strategy of the company. He is dedicated to commercializing FDS’s acoustic platform into multiple markets. His current market focus is life sciences where FDS’s patented 3D force field provides delicate handling, selection and sorting of cells for both scaling up and out. He boldly believes that their innovative cell handling engine can enable the 4th pillar of medicine while significantly driving down the costs of cell and gene therapy. This ultimately brings the manufacturing closer to the patient. Stanley possesses an insatiable entrepreneurial drive. He is Chairman of the board at FloDesign and founding CEO of FloDesign Wind Turbine, FloDesign Water Turbine and FloDesign Sonics. Throughout Mr. Kowalski’s career, he has helped to engineer and deliver many products to market, with a core focus on science-based, enabling technologies.

Daniella Kranjac is a Co-Founder and General Partner at Dynamk Capital, a venture capital fund investing in startup and growth companies in life sciences tools, technologies and services. Dynamk’s mission is to help companies reach their full potential providing access to capital, strategy, business development and flawless commercial execution. Daniella began her career as a Co-Founder of Wave Biotech LLC where she drove the growth of a disruptive technology, leading the $30 million group to a successful exit and acquisition by GE Healthcare in 2007. At GE, Daniella held several business development & commercial leadership roles, establishing a several hundred million dollar enterprise solutions business.Daniella’s unique perspective on the global healthcare market is owed to varied experiences in pharma, biologics and biosimilars, vaccines and cell therapies as these markets have evolved in the United States, Europe, Latin America, China and the Middle East.

DOI: 10.18609/cgti.2018.037
Citation: Cell Gene Therapy Insights 2018; 4(4), 337-344.
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog